Home Science Biotech Visionary Is Skeptical About AI’s Impact on...
Science

Biotech Visionary Is Skeptical About AI’s Impact on Medical Innovation

Biotech Visionary Is Skeptical About AI’s Impact on Medical Innovation
Key Points

Biotech Visionary Is Skeptical About AI’s Impact on Medical Innovation The inventor of the groundbreaking Crispr gene-editing technology is skeptical about artificial intelligence replacing human effort in the realm of scientific discovery, adding to a growing debate over its impact on medical research and innovation. Crispr-Cas9 gene editing rocked the scientific world when it was first introduced in 2012, earning Jennifer Doudna, professor of biochemistry at the University of California...

Biotech Visionary Is Skeptical About AI’s Impact on Medical Innovation The inventor of the groundbreaking Crispr gene-editing technology is skeptical about artificial intelligence replacing human effort in the realm of scientific discovery, adding to a growing debate over its impact on medical research and innovation. Crispr-Cas9 gene editing rocked the scientific world when it was first introduced in 2012, earning Jennifer Doudna, professor of biochemistry at the University of California Berkeley, the 2020 Nobel Prize in Chemistry. In an interview with Bloomberg’s The Circuit with Emily Chang, Doudna challenged the idea that OpenAI Inc.’s ChatGPT might soon get credit for drug discovery.
Crispr (PERSON) Jennifer Doudna (PERSON) the University of California Berkeley (ORG) Bloomberg’s The Circuit (ORG) Emily Chang (PERSON) Doudna (PERSON) OpenAI Inc.’s (ORG)
Originally published by Bloomberg Technology Read original →